Skip to main content

HPV Infection

13
Pipeline Programs
16
Companies
15
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
1
0
1
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
4100%
+ 16 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
3
Gardasil 9 2 dose regimenPhase 4
Gardasil ® 9Phase 4
Quadrivalent Human PapillomavirusPhase 4
MSD
MSDIreland - Ballydine
3 programs
3
Gardasil 9 2 dose regimenPhase 41 trial
Gardasil ® 9Phase 41 trial
Quadrivalent Human PapillomavirusPhase 41 trial
Active Trials
NCT04206813Active Not Recruiting352Est. Oct 2026
NCT04982614Completed1,403Est. Dec 2024
NCT05435209Completed158Est. Oct 2023
Hope Medicine
Hope MedicineChina - Pudong
1 program
1
HPV vaccinePhase 3Vaccine1 trial
Active Trials
NCT05173324Not Yet Recruiting8,000Est. Jun 2027
Bovax Biotechnology
Bovax BiotechnologyChina - Chongqing
1 program
1
Medium dose for 15-HPV vaccinePhase 2Vaccine1 trial
Active Trials
NCT06756269Recruiting330Est. Jan 2026
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
ChAdOx1-HPVPhase 1/2
Barinthus Biotherapeutics
1 program
1
ChAdOx1-HPVPhase 1/21 trial
Active Trials
NCT04607850Completed108Est. Jan 2024
BlueSky Immunotherapies
BlueSky ImmunotherapiesAustria - Vienna
2 programs
2
FluBHPVE6E7Phase 11 trial
FluBHPVE6E7Phase 11 trial
Active Trials
NCT05829629Recruiting20Est. Nov 2025
NCT04490512Completed28Est. Jun 2023
Design Pharmaceuticals
1 program
1
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous usePhase 1Vaccine
Lee's Pharmaceutical
Lee's PharmaceuticalChina - Guangzhou
2 programs
Recombinant Human Interferon a-2b GelPHASE_21 trial
Yallaferon®PHASE_2_31 trial
Active Trials
NCT02593968Unknown100Est. Nov 2016
NCT01824992Completed325Est. Sep 2012
Switch Therapeutics
Switch TherapeuticsCA - South SF
1 program
Clinical Correlation Between Self-collected and Physician-collected HPV Screening KitsN/A1 trial
Active Trials
NCT05679141Completed344Est. Mar 2024
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
ObservationN/A1 trial
Active Trials
NCT06631495Not Yet Recruiting100,000Est. Oct 2027
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Physician Communication 2 VirtualN/A1 trial
Active Trials
NCT05336240Recruiting120Est. Dec 2026
Design Therapeutics
1 program
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous usePHASE_1Vaccine1 trial
Active Trials
NCT06959563Active Not Recruiting20Est. Sep 2026
Papivax
PapivaxTaiwan - Taipei
1 program
pBI-11PHASE_21 trial
Active Trials
NCT06210854Not Yet Recruiting48Est. Mar 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
MSDQuadrivalent Human Papillomavirus
MSDGardasil ® 9
MSDGardasil 9 2 dose regimen
Hope MedicineHPV vaccine
Lee's PharmaceuticalYallaferon®
PapivaxpBI-11
Bovax BiotechnologyMedium dose for 15-HPV vaccine
Lee's PharmaceuticalRecombinant Human Interferon a-2b Gel
Barinthus BiotherapeuticsChAdOx1-HPV
Design Therapeutics9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
BlueSky ImmunotherapiesFluBHPVE6E7
BlueSky ImmunotherapiesFluBHPVE6E7
UNION therapeuticsObservation
Colorado TherapeuticsPhysician Communication 2 Virtual
Switch TherapeuticsClinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

Clinical Trials (15)

Total enrollment: 111,356 patients across 15 trials

NCT05435209MSDQuadrivalent Human Papillomavirus

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

Start: May 2022Est. completion: Oct 2023158 patients
Phase 4Completed
NCT04982614MSDGardasil ® 9

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Start: Apr 2022Est. completion: Dec 20241,403 patients
Phase 4Completed
NCT04206813MSDGardasil 9 2 dose regimen

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

Start: Dec 2020Est. completion: Oct 2026352 patients
Phase 4Active Not Recruiting
NCT05173324Hope MedicineHPV vaccine

Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial

Start: Feb 2023Est. completion: Jun 20278,000 patients
Phase 3Not Yet Recruiting
NCT01824992Lee's PharmaceuticalYallaferon®

Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections

Start: Mar 2011Est. completion: Sep 2012325 patients
Phase 2/3Completed
NCT06210854PapivaxpBI-11

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Start: May 2026Est. completion: Mar 203048 patients
Phase 2Not Yet Recruiting
NCT06756269Bovax BiotechnologyMedium dose for 15-HPV vaccine

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

Start: Jan 2025Est. completion: Jan 2026330 patients
Phase 2Recruiting
NCT02593968Lee's PharmaceuticalRecombinant Human Interferon a-2b Gel

Yallaferon in Chinese Population

Start: Sep 2015Est. completion: Nov 2016100 patients
Phase 2Unknown
NCT04607850Barinthus BiotherapeuticsChAdOx1-HPV

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Start: Mar 2021Est. completion: Jan 2024108 patients
Phase 1/2Completed
NCT06959563Design Therapeutics9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

Start: Apr 2025Est. completion: Sep 202620 patients
Phase 1Active Not Recruiting
NCT05829629BlueSky ImmunotherapiesFluBHPVE6E7

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Start: Sep 2023Est. completion: Nov 202520 patients
Phase 1Recruiting
NCT04490512BlueSky ImmunotherapiesFluBHPVE6E7

Study of FluBHPVE6E7 in HPV-16 Infected Women

Start: Dec 2020Est. completion: Jun 202328 patients
Phase 1Completed
NCT06631495UNION therapeuticsObservation

All-cause and Diseases-specific Mortality of High-risk HPV Infection

Start: Oct 2024Est. completion: Oct 2027100,000 patients
N/ANot Yet Recruiting
NCT05336240Colorado TherapeuticsPhysician Communication 2 Virtual

PCOM2 - The Physician Communication Intervention, Version 2.0

Start: Nov 2023Est. completion: Dec 2026120 patients
N/ARecruiting
NCT05679141Switch TherapeuticsClinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

Start: Feb 2023Est. completion: Mar 2024344 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 111,356 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.